Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

Actiphage identifies strain of mycobacteria in blood of bison

Results presented at ICP (12-16th June) from first study in North American bison, shows capacity of Actiphage to sub-type mycobacteria in blood.
  • May 26, 2022
  • Latest, MAP, Other animals
bison MAP diagnostic

The role of Actiphage® as a powerful research tool for tuberculosis-related diseases is to be explored at the 15th International Association for Paratuberculosis Colloquium (ICP2022) in Dublin on 12 – 16th June 2022. Results from a study of co-infection of bison will be presented and the new Johne’s Disease Testing Service will be discussed on the Biosellal stand where PBD Biotech has a presence.


First results show Actiphage detects co-infection in bison

The poster, to be presented by Professor Cath Rees of the University of Nottingham, is the first time that Actiphage has been applied to detecting co-infection of North American bison. The nature of infection in the seven bison was unknown, so Actiphage was used as a lysing agent to extract DNA from viable mycobacterial cells, then different PCR assays were applied to identify the type of Mycobacterium causing the infection.

Actiphage
Microscopy image of bacteriophage (orange) and a mycobacterium (green) (c) PBD Biotech

The robust nature of the mycobacteria means that extracting the DNA for identification by PCR is problematic and physical or chemical lysis methods are inefficient. In contrast, the phage lysis has evolved to be highly efficient and allows Actiphage to detect very low (<10) numbers of cells.

Additionally, since the assay directly detects the presence of the organism rather than an immune response, the method can be applied to any species of animal. Actiphage’s developer, PBD Biotech, has recently launched a Johne’s Disease testing service that uses Actiphage to detect Mycobacterium avium subsp. paratuberculosis (MAP) in the blood of cattle and farmed deer.

The bison study successfully identified the presence of MAP in six animals, of which two also had evidence of M. avium co-infection; in the remaining animal only M. avium was detected. This is an important finding as it shows Actiphage is a powerful tool for disease management in species where there is limited availability of immunological tests.

The results demonstrate the ability of Actiphage to successfully extract DNA even when few cells of viable Mycobacteria are present, and offers a utility for both rapid detection and sub-speciation due to it compatibility with existing PCR-based assays.

Early detection of MAP in calves

Actiphage has also been used to detect MAP in the blood of experimentally infected calves (Swift et al., 2020).

Earlier findings from a study by Biosellal and PBD Biotech found that MAP could be detected in the blood of day-old calves born from MAP-positive mothers. Previously Johne’s Disease was only reliably diagnosed in 18 – 24-month calves after they had started to shed MAP into their faeces.

The study involved monthly testing on calves from three different herds – born from MAP-positive and MAP-negative cows – using PBD Biotech’s Actiphage kit and Biosellal’s Bio-T kit® MAP PCR on blood samples. This landmark study showed that there was a window of opportunity between birth and shedding of MAP to detect and control the disease.

See us at ICP on Biosellal stand

Jonnie Yewdall, Commercial Director for PBD Biotech, will be available for discussions at the Biosellal stand at ICP. The Biosellal PCR kit is verified and validated to detect MAP and works with Actiphage.

Diagnostics and detection – Poster Pitches

Tuesday, June 14, 2022, 12:45 PM – 1:00 PM, Main Auditorium, Printworks

Detection of MAP and M. avium co-infection in North American Bison using Actiphage – Prof Cath Rees

Optimization of Actiphage for detection of MAP in different hosts, including humans – Prof Cath Rees

More about ICP 2022

Share:

Related posts

Loading...
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.
global unmet need for rapid molecular diagnostic for human TB

Targeting global unmet need for rapid molecular diagnostic for human TB

January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis...
Marie Roskrow

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

January 17, 2023
Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need, PBD Biotech is announcing that it has appointed Dr Marie Roskrow to chair its board and has expanded its scientific...
Marie Roskrow

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

January 17, 2023
Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need,...
TB Progression in humans

Words Matter – how a shared language will accelerate development of TB diagnostics

December 21, 2022
Creating a shared language for talking about tuberculosis has been identified by the Stop TB Partnership as being a constructive step towards achieving the United Nations political declaration to eliminate TB by 2030.
TB Progression in humans

Words Matter – how a shared language will accelerate development of TB diagnostics

December 21, 2022
Creating a shared language for talking about tuberculosis has been identified by the Stop TB Partnership as being a constructive...
TAG pipeline report on TB feat

Detecting subclinical TB – Actiphage only blood test for mycobacteria highlighted in TAG pipeline report

November 22, 2022
Actiphage is the only test in development for subclinical tuberculosis that directly detects mycobacteria in the blood, it has been revealed by the TAG pipeline report
TAG pipeline report on TB feat

Detecting subclinical TB – Actiphage only blood test for mycobacteria highlighted in TAG pipeline report

November 22, 2022
Actiphage is the only test in development for subclinical tuberculosis that directly detects mycobacteria in the blood, it has been...
1 2 … 24 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More